ATE213411T1 - Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen - Google Patents

Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen

Info

Publication number
ATE213411T1
ATE213411T1 AT94903295T AT94903295T ATE213411T1 AT E213411 T1 ATE213411 T1 AT E213411T1 AT 94903295 T AT94903295 T AT 94903295T AT 94903295 T AT94903295 T AT 94903295T AT E213411 T1 ATE213411 T1 AT E213411T1
Authority
AT
Austria
Prior art keywords
phenserine
medications
treatment
production
cognitive disorders
Prior art date
Application number
AT94903295T
Other languages
English (en)
Inventor
Nigel H Greig
Arnold Brossi
Timothy T Soncraint
Harold W Pooks Holloway
Stanley I Rapoport
Setsu Iijima
Edward L Spangler
Donald K Ingram
Xue Feng Pei
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE213411T1 publication Critical patent/ATE213411T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94903295T 1992-11-23 1993-11-23 Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen ATE213411T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/980,399 US5409948A (en) 1992-11-23 1992-11-23 Method for treating cognitive disorders with phenserine
PCT/US1993/011423 WO1994012176A1 (en) 1992-11-23 1993-11-23 Use of phenserine to treat cognitive disorders

Publications (1)

Publication Number Publication Date
ATE213411T1 true ATE213411T1 (de) 2002-03-15

Family

ID=25527533

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903295T ATE213411T1 (de) 1992-11-23 1993-11-23 Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen

Country Status (11)

Country Link
US (1) US5409948A (de)
EP (1) EP0668763B1 (de)
JP (1) JP3778363B2 (de)
AT (1) ATE213411T1 (de)
AU (1) AU693428B2 (de)
CA (1) CA2149924C (de)
DE (1) DE69331605T2 (de)
DK (1) DK0668763T3 (de)
ES (1) ES2173111T3 (de)
PT (1) PT668763E (de)
WO (1) WO1994012176A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002154A1 (en) * 1997-07-09 1999-01-21 Axonyx Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
US20030125609A1 (en) * 2001-08-03 2003-07-03 Robert Becker Method for reliable measurement in medical care and patient self monitoring
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20040024043A1 (en) * 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7897639B2 (en) 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005089746A1 (en) * 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
JP2007529556A (ja) * 2004-03-19 2007-10-25 アクソニクス インコーポレイテッド 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
CA2508585A1 (en) * 2004-06-01 2005-12-01 Axonyx, Inc. Transdermal delivery system for treatment of cognitive disorders
EP1604686A1 (de) * 2004-06-08 2005-12-14 Axonyx, Inc. Verwendung von Phenserine und einem HMG CoA reduktase Hemmer zur Verzögerung der Alzheimer Krankheit
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US20070167509A1 (en) * 2005-06-14 2007-07-19 Joseph Araujo Use of phenserine and analogs to treat behavioral problems and improve trainability
US8101782B2 (en) * 2007-02-02 2012-01-24 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
RU2327480C1 (ru) 2007-05-23 2008-06-27 Виктор Иванович Рощин Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
WO2009011901A2 (en) * 2007-07-18 2009-01-22 Colucid Pharmaceuticals, Inc. Methods for promoting wakefulness
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
WO2010065743A2 (en) 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
EP2453890B1 (de) * 2009-07-17 2020-05-27 Allergan, Inc. Zusammensetzungen mit einem cholinesterasehemmer zur behandlung von kognitiven beeinträchtigungen
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
TW201717938A (zh) 2015-08-14 2017-06-01 Ｑｒ製藥股份有限公司 治療或預防急性腦部或神經損傷的方法
US10111860B1 (en) 2016-01-15 2018-10-30 Aristea Translational Medicine Corporation Compositions and methods for treating concussion
US10864192B2 (en) 2016-01-15 2020-12-15 Aristea Translational Medicine Corporation Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions
EP3654957A4 (de) 2017-05-24 2021-06-23 Annovis Bio, Inc. Prävention oder behandlung von krankheitszuständen aufgrund von metall-dis-homöostase durch verabreichung von posiphen an gesunde oder kranke menschen
WO2022245843A1 (en) 2021-05-18 2022-11-24 Annovis Bio, Inc. Inhibition of neurological injuries due to infections via administration of butanetap and analogs thereof
WO2025017530A1 (en) 2023-07-19 2025-01-23 Assia Chemical Industries Ltd. Solid state forms of buntanetap and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US479107A (en) * 1892-07-19 oesterreich
US4791107A (en) * 1986-07-16 1988-12-13 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use
DE3843239C1 (de) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US4971992A (en) * 1989-03-27 1990-11-20 Hoechst-Roussel Pharmaceuticals Inc. Carbonate derivatives of eseroline
US4996201A (en) * 1989-08-02 1991-02-26 Warner-Lambert Co. 4-(N-substituted amino)-2-butynyl-1-carbamates and thiocarbamates and derivatives thereof as centrally acting muscarinic agents
US4914102A (en) * 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
US5077289A (en) * 1989-11-30 1991-12-31 Hoechst Roussel Pharmaceuticals Inc. Memory enhancing and analgesic aminocarbonylcarbamates related to physostigmine
US5171750A (en) * 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase

Also Published As

Publication number Publication date
US5409948A (en) 1995-04-25
WO1994012176A1 (en) 1994-06-09
DE69331605T2 (de) 2002-10-31
DE69331605D1 (de) 2002-03-28
DK0668763T3 (da) 2002-06-03
CA2149924C (en) 2006-01-31
PT668763E (pt) 2002-08-30
ES2173111T3 (es) 2002-10-16
EP0668763A1 (de) 1995-08-30
AU5729094A (en) 1994-06-22
CA2149924A1 (en) 1994-06-09
EP0668763B1 (de) 2002-02-20
AU693428B2 (en) 1998-07-02
JPH08505130A (ja) 1996-06-04
JP3778363B2 (ja) 2006-05-24

Similar Documents

Publication Publication Date Title
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
DE69825292D1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE127342T1 (de) Verwendung von modafinil zur herstellung eines antiischämischen arzneimittels.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE204704T1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69424777D1 (de) 3,4-diarylchromane zur behandlung von dermatitis
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
ATE196738T1 (de) Verwendung von immunglobulin-präparationen zur herstellung eines medikaments zur oralen verabreichung zur behandlung und prophylaxe chronischer schmerzzustände
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
ATE142875T1 (de) Methode zur behandlung von haarausfall
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE294584T1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
HU910436D0 (en) Process for the production of medical preparations for treating apnoea during sleep
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee